Mechanism of coordinated access to orphan drugs
نویسندگان
چکیده
Context Although the EU Council stated[1] that “All health systems in the EU aim to make provision, which is patient-centered and responsive to individual need”, numerous sources show important and unacceptable differences in access to orphan drugs in the Member States of the European Union (EU COM [2], EURORDIS [3,4], BE EU Presidency [5,8], EU Council [6]). With this regard, in the context of the 2010 Belgian EU presidency initiative on ‘Innovation and Solidarity’ and within the framework of the process on corporate responsibility in the field of pharmaceuticals [7], EU Commissioner Tajani launched the project Mechanism of Coordinated Access to Orphan Drugs.
منابع مشابه
A company experience of the first MoCA pilot project
Background Pricing and reimbursement authorities often lack sufficient information to decide about Orphan Medicinal Products (OMPs), because of pricing, high levels of uncertainty and small datasets, amongst others. EU Member States share similar challenges as they seek to include OMPs appropriately in their healthcare systems. The “Process on Corporate Responsibility in the field of Pharmaceut...
متن کاملAccess to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
OBJECTIVE To review existing regulations and policies utilised by countries to enable patient access to orphan drugs. METHODS A review of the literature (1998 to 2014) was performed to identify relevant, peer-reviewed articles. Using content analysis, we synthesised regulations and policies for access to orphan drugs by type and by country. RESULTS Fifty seven articles and 35 countries were...
متن کاملMarket access of orphan drugs and the role of multi-criteria decision making
Background A number of factors play a role in market access of orphan drugs, such as the extent to which an orphan drug meets a medical need; existence of alternative health technologies; disease prevalence; number of orphan drug indications; and added clinical benefit of the orphan drug. How can these factors be taken into account in market access decisions given that there is uncertainty over...
متن کاملSome Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012
We examined whether access to US-approved orphan drugs in Canada has changed between 1997 (when Canada chose not to adopt an orphan drug policy) and 2012 (when Canada reversed its policy decision). Specifically, we looked at two dimensions of access to US-approved orphan drugs in Canada: (1) regulatory access; and (2) temporal access. Whereas only 63% of US-approved orphan drugs were granted re...
متن کاملEthical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
BACKGROUND More than 6,800 rare diseases and conditions have been identified in the US, which affect 25-30 million Americans. In 1983, the US Congress enacted the Orphan Drug Act (ODA) to encourage the development and marketing of drugs to treat rare diseases and conditions. This study analyzed all orphan designations and FDA approvals since 1983 through 2015, discussed the effectiveness of inc...
متن کامل